Bethanechol Shortage: What Providers and Prescribers Need to Know in 2026

Bethanechol chloride occupies a narrow but important niche in the pharmacologic management of nonobstructive urinary retention and neurogenic bladder atony. While the drug is not currently listed as an official FDA shortage in 2026, prescribers are increasingly fielding calls from patients unable to locate it at their usual pharmacy. This brief summarizes the current landscape and offers guidance for clinical management.

Current Supply Status (2026)

Bethanechol chloride tablets (5 mg, 10 mg, 25 mg, 50 mg) are currently available from multiple FDA-approved generic manufacturers in the U.S. The drug is NOT on the FDA Drug Shortages Database as of 2026. However, stocking patterns at the retail pharmacy level are inconsistent because bethanechol has a low national prescription volume.

The brand-name Urecholine is no longer actively marketed. The medication now exists only in generic form, with no major manufacturer conducting promotional activities that would drive broad retail stocking. This dynamic means that even nationally available drugs can create localized access problems for patients.

Clinical Context: Who Is Prescribed Bethanechol?

The primary prescribing specialties for bethanechol include urology, neurology, physiatry (PM&R), and obstetrics/gynecology. Primary care providers may also prescribe it for uncomplicated postoperative or postpartum urinary retention. A 2019 analysis in the International Journal of Clinical Practice estimated that bethanechol was prescribed in approximately 0.8% of clinic visits for urinary tract symptoms in women over a 10-year study period — highlighting that this is a relatively low-volume prescription drug nationally.

When Should You Recommend Bethanechol?

FDA-approved indications for bethanechol chloride are:

Acute postoperative nonobstructive (functional) urinary retention

Postpartum nonobstructive functional urinary retention

Neurogenic atony of the urinary bladder with retention

Bethanechol is most useful in patients with detrusor hypocontractility and intact, functional sphincters. It is contraindicated in mechanical obstruction and in patients with significant comorbidities including asthma, coronary artery disease, epilepsy, Parkinson's disease, bradycardia, hypotension, and peptic ulcer. Ensure a thorough contraindication review prior to prescribing.

Key Drug Interactions to Review

Important interactions that warrant clinical attention:

Anticholinergic medications (oxybutynin, solifenacin, tolterodine, diphenhydramine): Pharmacologically oppose bethanechol's muscarinic agonist effects. Concurrent use negates therapeutic benefit.

Acetylcholinesterase inhibitors (donepezil, rivastigmine, galantamine): Additive cholinergic effects — increased risk of adverse muscarinic events (bradycardia, bronchospasm, excessive salivation).

Ganglion-blocking agents (mecamylamine): Additive hypotension risk.

Sympathomimetics (phenylephrine, pseudoephedrine): Counteract bethanechol's cholinergic actions at receptor sites.

38,004+ patients found their medications in stock

38K+

Find Bethanechol In Stock Today →

Clinical Alternatives When Bethanechol Is Unavailable

When bethanechol is not accessible for a patient who requires treatment for urinary retention, consider the following based on the clinical scenario:

Alpha-1 adrenergic blockers (tamsulosin, alfuzosin, silodosin): Effective for outlet resistance reduction; may be used in combination with bethanechol when both detrusor underactivity and elevated urethral tone are present.

Clean intermittent catheterization (CIC): Often the most reliable approach for significant neurogenic bladder atony. Consider CIC as a bridge while bethanechol is being located.

Compounding pharmacies: For patients who require bethanechol long-term, a compounding pharmacy can prepare customized formulations if commercial supply is temporarily unavailable at retail level.

Sacral neuromodulation: For patients with chronic conditions unresponsive to pharmacotherapy.

Counseling Patients on Locating Bethanechol

Advise patients to try multiple pharmacies and ask about special orders (typically 24–48 hours). medfinder for providers is a service that calls local pharmacies on the patient's behalf to check inventory, saving time and reducing patient burden. Many prescribers now refer patients to medfinder as a first step when a medication is not available at their preferred pharmacy.

Skip the calls, skip the stress.

Find Bethanechol In Stock Today →

50K+

Medications
Found

99%

Success
Rate

6+

Hours saved
on average

Dosing Reminder for Clinical Practice

Standard adult oral dosing for bethanechol is 10–50 mg three to four times daily. To determine minimum effective dose, begin with 5–10 mg and repeat at hourly intervals until satisfactory voiding occurs or a maximum of 50 mg is reached in that titration period. The drug should be taken on an empty stomach (one hour before or two hours after meals) to minimize GI adverse effects. Atropine should be available as an antidote for overdose, particularly after subcutaneous administration.

Summary for Prescribers

Bethanechol chloride remains available in 2026 but requires proactive pharmacy sourcing due to its low market volume. Counsel patients on alternatives including special orders, medfinder, and independent pharmacies. For the patient-facing version of this information, see: Bethanechol Shortage Update: What Patients Need to Know in 2026.